
Drug Safety Signal Evaluation & Causality Assessment
Evaluate drug safety signals using structured causality assessment
What You Can Do
You systematically evaluate drug safety signals using structured causality assessment frameworks—applying WHO-Naranjo-Kramer methodologies, synthesizing real-world evidence from claims and EHR data, and generating regulatory-ready analyses. This skill transforms raw adverse event data into publication-quality evidence and compliant regulatory submissions with quantified confidence intervals and bias assessments.
Features
Example Output
Causality Assessment Summary
| Category | Score | Interpretation |
|---|---|---|
| WHO-UMC | Probable (8/13) | Temporal relationship strong; alternative explanations less likely |
| Naranjo | 8/13 | Probable adverse drug reaction |
| Strength of Association | OR 2.8 (95% CI: 1.9–4.1) | Statistically significant 2.8× increased risk |
Regulatory Finding: Signal meets EMA pharmacovigilance criteria for expedited review. Recommend risk minimization strategy targeting high-risk subgroups (age >65: OR 4.2; concurrent NSAIDs: OR 3.1).
Publication Statement: "Propensity-score adjusted analysis identified dose-dependent signal (p=0.003), unconfounded by renal function and drug interactions, supporting strengthened product labeling."
What's Included
- SKILL.md: Complete causality assessment framework with decision trees and scoring logic
- Causality Worksheets: WHO-UMC, Naranjo, and Kramer scoring templates with interpretation guides
- Regulatory Templates: FDA Form 3500A narrative structure, EMA Line Listing format, ICSR XML checklist
- Statistical Analysis Checklist: Odds ratio calculation, confounding adjustment methods, sensitivity tests
- Real-World Evidence Evaluation: Criteria for claims data validity, EHR phenotype validation, registry assessment
- Signal Evaluation Decision Tree: Workflow for classifying signals and recommending follow-up actions
- Bias & Confounding Framework: Systematic assessment of selection bias, information bias, and confounders by study design
Who It's For
- Pharmacovigilance specialists & medical safety officers — Evaluate incoming adverse event reports for regulatory reporting
- Regulatory affairs professionals — Prepare safety data packages and risk-benefit assessments for submissions
- Epidemiologists & biostatisticians — Conduct signal quantification and real-world evidence studies
- Clinical research scientists — Design post-marketing surveillance and safety analyses
- Drug safety consultants — Guide pharmaceutical and biotech clients through causality assessment processes
Best For
- Evaluating adverse event causality — Apply structured frameworks to determine confidence in drug-event associations
- FDA/EMA regulatory submissions — Generate compliant safety reports with quantified evidence and risk assessments
- Publishing pharmacovigilance findings — Prepare statistical analyses and narrative results for peer-reviewed journals
- Post-marketing surveillance analysis — Synthesize real-world evidence from observational studies and registries
- Risk-benefit assessments — Stratify safety signals by patient subgroup for evidence-based labeling decisions







